IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Cambrex offers cutting-edge capabilities in peptide development and manufacturing, combining innovative technologies, diverse applications and specialized expertise to meet the growing demand for peptide-based therapeutics.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks. Cambrex specializes in seamless technology transfers and quick onboarding to keep your program on track.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
Discover Synthesis — our technical newsletter spotlighting the latest innovations and expert insights in pharmaceutical development and manufacturing. Each issue delivers concise updates on breakthrough science, process advancements and real-world solutions from trusted industry peers.
Thank you for your interest in our content.
In this month’s issue of Synthesis, we sit down with the winner of the 2025 Snapdragon Prize for Innovation in Chemistry Technology, Dr. Song Lin – Tisch University Professor in chemistry and chemical biology at Cornell University – to discuss his thoughts on groundbreaking electrosynthetic chemistry research, how will medicinal chemistry evolve, and what kids’ cartoon characters have to do with it all.
In recent years, increased investment in peptide manufacture has been a notable trend. We’ve rapidly moved from a time when very few people were talking about peptide manufacture to a point where it feels almost mandatory to have a foot in the peptide world. Peptides are hot property. But are we ready for them?
We’re excited to kick off 2026 by sharing the inaugural issue of Synthesis – Cambrex’s monthly collation of science, insight and perspectives from across the field of drug development and manufacture. Inspired by our work in the lab and in the plant, it reflects our hope that sharing questions, ideas and concepts leads to new thoughts and solutions.